Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Kim Discusses the Primary Efficacy Results From the B-F1RST Trial in NSCLC

October 23rd 2018

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the primary efficacy results from the B-F1RST trial in non–small cell lung cancer (NSCLC).

Mutation Testing for All Patients With NSCLC

October 23rd 2018

Advances in RET Inhibition in NSCLC

October 23rd 2018

Response Rates in Treatment of MET-Amplified NSCLC

October 23rd 2018

Targeting HER2 Mutations in NSCLC: What Do We Know?

October 23rd 2018

NTRK Gene Fusions: Rare Yet Actionable

October 23rd 2018

Additional Targets in NSCLC: BRAF V600E and BRAF Variants

October 23rd 2018

Second Generation ALK Inhibitors in NSCLC

October 23rd 2018

Practice-Changing Frontline Treatment of ALK+ NSCLC

October 23rd 2018

Updates in the Treatment of ALK+ and ROS1+ NSCLC

October 23rd 2018

Adjuvant TKI for Early Stage EGFR+ NSCLC

October 23rd 2018

Frontline Chemo and TKI Combination in EGFR+ NSCLC

October 23rd 2018

Promising EGFR Inhibitors in Development for NSCLC

October 23rd 2018

Resistance Mechanisms and Sequencing for EGFR+ NSCLC

October 23rd 2018

Advances in Frontline Therapy for EGFR+ NSCLC

October 23rd 2018

Frontline Alectinib Outperforms Crizotinib in Asian Patients With ALK+ NSCLC

October 23rd 2018

Asian patients with untreated ALK-positive advanced NSCLC lived significantly longer without disease progression if they received the next-generation tyrosine kinase inhibitor alectinib instead of crizotinib as initial therapy.

Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel Improves OS in Nonsquamous NSCLC

October 22nd 2018

The first-line triplet of atezolizumab, carboplatin, and nab-paclitaxel was associated with a statistically significant improvement in both progression-free and overall survival compared with chemotherapy alone in patients with stage IV nonsquamous NSCLC, according to results from the phase III IMpower130 trial.

FDA Extends Review Period for Frontline Nivolumab/Ipilimumab in TMB-High NSCLC

October 22nd 2018

The FDA has added 3 months to the review period for the combination of nivolumab plus low-dose ipilimumab for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.

Entrectinib Active Across Multiple Tumor Types

October 22nd 2018

More than half of patients with advanced solid tumors associated with NTRK gene fusions responded to treatment with the small-molecule inhibitor entrectinib, an integrated analysis of 3 clinical trials showed.

Tepotinib Plus Gefitinib Improves PFS in MET+ EGFR-Mutant NSCLC

October 21st 2018

The combination of tepotinib plus gefitinib improved progression-free survival and overall response versus chemotherapy in patients with MET mutated EGFR-positive non–small cell lung cancer resistant to prior EGFR TKI therapy.